{"url_path":"/sec/gplb/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1392449/0001654954-26-004971-index.html","accession_number":"0001654954-26-004971","cik":"0001392449","ticker":"GPLB","issuer_name":"Green Planet Bio Engineering Co. Ltd.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1392449/0001654954-26-004971-index.html","primary_entity_key":"0001392449","primary_entity_name":"Green Planet Bio Engineering Co. Ltd."},"word_count":915,"has_tables":true,"body_markdown":"gplb_10q.htm\n0001392449false--12-31falseQ120260.001100000000000.001250000000200064022000640220006402falsefalsefalsefalse0.0011000000000013924492026-01-012026-03-310001392449us-gaap:SubsequentEventMember2025-03-292026-04-010001392449us-gaap:SeriesAPreferredStockMember2025-12-310001392449us-gaap:SeriesAPreferredStockMember2026-03-310001392449us-gaap:RetainedEarningsMember2026-03-310001392449us-gaap:AdditionalPaidInCapitalMember2026-03-310001392449us-gaap:CommonStockMember2026-03-310001392449us-gaap:RetainedEarningsMember2026-01-012026-03-310001392449us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001392449us-gaap:CommonStockMember2026-01-012026-03-310001392449us-gaap:PreferredStockMember2026-01-012026-03-310001392449us-gaap:RetainedEarningsMember2025-12-310001392449us-gaap:AdditionalPaidInCapitalMember2025-12-310001392449us-gaap:CommonStockMember2025-12-310001392449us-gaap:PreferredStockMember2025-12-3100013924492025-03-310001392449us-gaap:RetainedEarningsMember2025-03-310001392449us-gaap:AdditionalPaidInCapitalMember2025-03-310001392449us-gaap:CommonStockMember2025-03-310001392449us-gaap:RetainedEarningsMember2025-01-012025-03-310001392449us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001392449us-gaap:CommonStockMember2025-01-012025-03-310001392449us-gaap:PreferredStockMember2025-01-012025-03-3100013924492024-12-310001392449us-gaap:RetainedEarningsMember2024-12-310001392449us-gaap:AdditionalPaidInCapitalMember2024-12-310001392449us-gaap:CommonStockMember2024-12-310001392449us-gaap:PreferredStockMember2024-12-3100013924492025-01-012025-03-3100013924492025-12-3100013924492026-03-3100013924492026-05-15iso4217:USDxbrli:sharesiso4217:USDxbrli:shares\n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, DC 20549**\n\n_______________________\n\n \n\n**FORM 10-Q**\n\n**_______________________**\n\n**(Mark One)**\n\n☒\n\nQuarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934\n\n \n\nFor the quarterly period ended **March 31, 2026**\n\n \n\nor\n\n \n\n☐\n\nTransition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934\n\n \n\nFor the transition period from___________ to ____________\n\n \n\nCommission file number **000-52622**\n\n \n\n**GREEN PLANET BIOENGINEERING CO., LTD.**\n\n(Exact Name of Registrant as Specified in its charter)\n\n \n\n**Delaware**\n\n \n\n**37-1532842**\n\n(State or other jurisdiction of\n\n \n\n(I.R.S. Employer\n\nincorporation or organization)\n\n \n\nIdentification No.)\n\n \n\n \n\n \n\n**20807 Biscayne Blvd., Suite 203,**\n\n**Aventura, Florida******\n\n \n\n**33180**\n\n(Address of principal executive offices)\n\n \n\n(Zip Code)\n\n \n\n**(786) 279-2900**\n\n(Registrant’s telephone number, including area code)\n\n \n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\n \n\nIndicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).\n\n \n\nIndicate by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):\n\n \n\nLarge accelerated filer\n\n☐\n\nAccelerated filer\n\n☐\n\nNon-accelerated filer\n\n☐\n\nSmaller reporting company\n\n☒\n\n                      (Do not check if a smaller company)                                   \n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ☒  No  ☐\n\n \n\nThe number of shares of common stock outstanding as of May 15, 2026 was 20,006,402.\n\n \n\n \n\n \n\n \n\nTABLE OF CONTENTS\n\n \n\n \n\n \n\n \n\n**Page Number**\n\n \n\n[**PART I**** FINANCIAL INFORMATION**](#p1)\n\n \n\n**4**\n\n \n\n \n\n \n\n \n\n \n\n[Item 1](#i1)\n\n**Financial Statements**\n\n \n\n**4**\n\n \n\n \n\n \n\n \n\n \n\n \n\n[Balance Sheets as of March 31, 2026 and Dec 31, 2025 (Unaudited)](#bc)\n\n \n\n4\n\n \n\n \n\n \n\n \n\n \n\n \n\n[Statements of Operations (Three Months Ended March 31, 2026 & 2025)](#soo)\n\n \n\n5\n\n \n\n \n\n \n\n \n\n \n\n \n\n[Statements of Stockholders’ Deficit (Three Months Ended March 31, 2026 & 2025)](#defict)\n\n \n\n6\n\n \n\n \n\n \n\n \n\n \n\n \n\n[Statements of Cash Flows (Three Months Ended March 31, 2026 & 2025)](#cf)\n\n \n\n7\n\n \n\n \n\n \n\n \n\n \n\n \n\n[Condensed Notes to the Financial Statements (Unaudited)](#notes)\n\n \n\n8\n\n \n\n \n\n \n\n \n\n \n\n \n\n[Item 2](#i2)\n\n[Management’s Discussion and Analysis of Financial Condition](#i2)\n\n \n\n10\n\n \n\n \n\n \n\n \n\n \n\n \n\n[Item 3](#i3)\n\n[Quantitative and Qualitative Disclosures about Market Risk](#i3)\n\n \n\n11\n\n \n\n \n\n \n\n \n\n \n\n \n\n[Item 4](#i4)\n\n[Controls and Procedures](#i4)\n\n \n\n11\n\n \n\n \n\n \n\n \n\n \n\n \n\n[**PART II****OTHER INFORMATION**](#p2)\n \n\n**12**\n\n \n\n \n\n \n\n \n\n \n\n[Item 1](#p2i1)\n\n[Legal Proceedings](#p2i1)\n\n \n\n12\n\n \n\n \n\n \n\n \n\n \n\n \n\n[Item 2](#p2i2)\n\n[Unregistered Sales of Equity Securities and Use of Proceeds](#p2i2)\n\n \n\n12\n\n \n\n \n\n \n\n \n\n \n\n \n\n[Item 3](#p2i3)\n\n[Defaults upon Senior Securities](#p2i3)\n\n \n\n12\n\n \n\n \n\n \n\n \n\n \n\n \n\n[Item 4](#p2i5)\n\n[Reserved](#p2i5)\n\n \n\n12\n\n \n\n \n\n \n\n \n\n \n\n \n\n[Item 5](#p2i4)\n\n[Other Information](#p2i4)\n\n \n\n12\n\n \n\n \n\n \n\n \n\n \n\n \n\n[Item 6](#p2i6)\n\n[Exhibits](#p2i6)\n\n \n\n12\n\n \n\n \n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\n**13**\n\n \n\n \n\n \n\n2\n\n*Table of Contents*\n\n \n\n   \n\n**INTERIM FINANCIAL STATEMENTS**\n\n \n\nThe unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States for interim financial information and with the instructions under Regulation S-X of the Securities and Exchange Commission (“SEC”) Form 10-Q. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. Therefore, these financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2025.\n\n \n\nThe financial statements included herein are unaudited; however, they contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the Company’s financial position as of the period reporting date, and the results of its operations and cash flows for the fiscal period end. The results of operations for the fiscal period end are not necessarily indicative of the results to be expected for future quarters or the full fiscal year.\n\n \n\n **FORWARD-LOOKING STATEMENTS**\n\n \n\nThis Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934.  These statements involve risks and uncertainties, including, among other things, statements regarding our business strategy, future revenues and anticipated costs and expenses.  Such forward-looking statements include, among others, those statements including the words “expects,” “anticipates,” “intends,” “believes,” “may,” “will,” “should,” “could,” “plans,” “estimates,” and similar language or negative of such terms.  Our actual results may differ significantly from those projected in the forward-looking statements.  Factors that might cause or contribute to such differences include, but are not limited to, those discussed in Item 2 “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”  You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this report.  Although we believe that the expectations reflected in the forward-looking statements are reasonable, we do not know whether we can achieve positive future results, levels of activity, performance, or goals.  Actual events or results may differ materially.  We undertake no obligation to publicly release any revisions to the forward-looking statements or reflect events or circumstances taking place after the date of this document.\n\n \n\n \n\n3\n\n*Table of Contents*\n\n \n\n**PART I FINANCIAL INFORMATION**"}